FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2331141141> ?p ?o ?g. }

• W2331141141 endingPage "A622" @default.
• W2331141141 startingPage "A622" @default.
• W2331141141 abstract "To assess the economic impact of Ceplene® with low-dose Interleukin-2 (IL-2) for the treatment of adult patients with Acute Myeloid Leukemia (AML) in first complete remission (CR-1) which previously received intensive chemotherapy in Spain. A budget impact model was developed using the perspective of the Spanish National Health System with a 4-year time horizon. Ceplene®/IL-2 was compared with no treatment and an unrelated allogenic hematopoietic stem cell transplant (allo-HSCT). For both treatment options and no treatment, health care costs (EUR 2013) including medical visits, hospitalisations, laboratory and diagnostic tests, prophylactic measures, treatment of complications and infections were considered. Average treatment costs per patient up to a maximum of three years were estimated for both treatment options and no treatment depending on the probability of overall survival without or with a relapse, and death without relapse, as well as the duration until relapse or death without relapse during this period. Total annual health care costs were estimated based on the annual per patient cost, the target population, and the market shares associated with each option, before and after the introduction of Ceplene®/IL-2. Patients eligible for Ceplene®/IL-2 were estimated at 1,502 in 2013 with a small increase up to 1,509 in 2016. The overall budget impact with the introduction of Ceplene®/IL-2, is estimated to decrease with €674,149 and €728,945 in 2014 and 2016, and an increase of €202,322 in 2015. Overall budget impact savings over the period 2014-2016 are estimated at €1,130,894. The introduction of Ceplene®/IL-2 as maintenance therapy supposes savings in the budget impact for the treatment of AML patients in CR-1 in Spain. Ceplene®/IL-2 is expected to fulfil a direct medical need for patients not eligible or having an unfavourable profile for an unrelated allo-HSCT receiving no treatment, and those who received an unrelated allo-HSCT with unfavourable prognostics." @default.
• W2331141141 created "2016-06-24" @default.
• W2331141141 creator A5029784332 @default.
• W2331141141 creator A5035036547 @default.
• W2331141141 creator A5046467060 @default.
• W2331141141 creator A5054608675 @default.
• W2331141141 date "2014-11-01" @default.
• W2331141141 modified "2023-10-06" @default.
• W2331141141 title "Budget Impact Model of Ceplene® As Maintenance Therapy in Adult Patients with Acute Myeloid Leukemia in First Remission" @default.
• W2331141141 doi "https://doi.org/10.1016/j.jval.2014.08.2205" @default.
• W2331141141 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27202193" @default.
• W2331141141 hasPublicationYear "2014" @default.
• W2331141141 type Work @default.
• W2331141141 sameAs 2331141141 @default.
• W2331141141 citedByCount "0" @default.
• W2331141141 crossrefType "journal-article" @default.
• W2331141141 hasAuthorship W2331141141A5029784332 @default.
• W2331141141 hasAuthorship W2331141141A5035036547 @default.
• W2331141141 hasAuthorship W2331141141A5046467060 @default.
• W2331141141 hasAuthorship W2331141141A5054608675 @default.
• W2331141141 hasBestOaLocation W23311411411 @default.
• W2331141141 hasConcept C126322002 @default.
• W2331141141 hasConcept C187212893 @default.
• W2331141141 hasConcept C194828623 @default.
• W2331141141 hasConcept C2776863199 @default.
• W2331141141 hasConcept C2778461978 @default.
• W2331141141 hasConcept C2778729363 @default.
• W2331141141 hasConcept C2908647359 @default.
• W2331141141 hasConcept C71924100 @default.
• W2331141141 hasConcept C99454951 @default.
• W2331141141 hasConceptScore W2331141141C126322002 @default.
• W2331141141 hasConceptScore W2331141141C187212893 @default.
• W2331141141 hasConceptScore W2331141141C194828623 @default.
• W2331141141 hasConceptScore W2331141141C2776863199 @default.
• W2331141141 hasConceptScore W2331141141C2778461978 @default.
• W2331141141 hasConceptScore W2331141141C2778729363 @default.
• W2331141141 hasConceptScore W2331141141C2908647359 @default.
• W2331141141 hasConceptScore W2331141141C71924100 @default.
• W2331141141 hasConceptScore W2331141141C99454951 @default.
• W2331141141 hasIssue "7" @default.
• W2331141141 hasLocation W23311411411 @default.
• W2331141141 hasLocation W23311411412 @default.
• W2331141141 hasOpenAccess W2331141141 @default.
• W2331141141 hasPrimaryLocation W23311411411 @default.
• W2331141141 hasRelatedWork W2161603182 @default.
• W2331141141 hasRelatedWork W2345640867 @default.
• W2331141141 hasRelatedWork W2350274480 @default.
• W2331141141 hasRelatedWork W2367183733 @default.
• W2331141141 hasRelatedWork W2388787066 @default.
• W2331141141 hasRelatedWork W2392998775 @default.
• W2331141141 hasRelatedWork W2393383561 @default.
• W2331141141 hasRelatedWork W2394313917 @default.
• W2331141141 hasRelatedWork W2936131736 @default.
• W2331141141 hasRelatedWork W3160786202 @default.
• W2331141141 hasVolume "17" @default.
• W2331141141 isParatext "false" @default.
• W2331141141 isRetracted "false" @default.
• W2331141141 magId "2331141141" @default.
• W2331141141 workType "article" @default.